ctDNA-Guided Intraventricular Therapy for CNS Malignancies

Starting soon · Not applicable

Conditions studied: Leptomeningeal Disease, Glioblastoma, Brain Metastases, Non-Small Cell Lung Cancer, Breast Cancer

In brief

This prospective, single-center study will evaluate whether cerebrospinal fluid (CSF) circulating tumor DNA (ctDNA) testing using the Belay Summit assay can improve the clinical management of patients with malignant gliomas or brain metastases from non-small cell lung cancer (NSCLC) or breast cancer who are suspected of having central nervous system (CNS) disease. Patients undergoing clinically indicated CSF evaluation will receive standard clinical testing, including CSF cytology and the Belay Summit ctDNA assay. Treatment decisions will remain at the discretion of the treating multidisciplinary neuro-oncology team. The primary objective is to evaluate 6-month clinical CNS progression-free survival (cCNS-PFS), with secondary objectives assessing safety and the association between CSF ctDNA dynamics and clinical outcomes. Exploratory proteogenomic analyses will be performed on residual CSF specimens when sufficient sample is available.

Key facts

Study ID

NCT07689721

Run by

Alireza Mansouri

People needed

77

Starts

2027-01-01

Expected to finish

2032-01-01

Last updated by the study team

2026-07-08

Who can join

Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥ 18 years.
• Diagnosis of histologically or cytologically confirmed HER2+ breast cancer, or triple negative breast cancer, or Stage IV non-small cell lung cancer, or recurrent high-grade glioma).
• Undergoing clinically indicated cerebrospinal fluid (CSF) collection as part of routine clinical care: CSF may be obtained via lumbar puncture or existing CSF access device. Decision for CSF collection must be made independently by the treating clinical team and not solely for research purposes.
• Detectable CSF ctDNA and/or positive CSF cytology, with consideration for CNS-directed management by the treating neuro-oncology team.
• Ability to provide informed consent, or availability of a legally authorized representative (LAR).

You may not qualify if…

• Age <18 years.
• Inability to provide informed consent and no legally authorized representative (LAR) available.
• Not undergoing clinically indicated CSF collection as part of standard clinical care.
• Absence of detectable CSF ctDNA and absence of positive CSF cytology.
• Not being considered for CNS-directed management by the treating neuro-oncology team.
• Clinical contraindications to CSF collection, including but not limited to: Significant intracranial mass effect; (e.g., midline shift >5 mm or effacement of basal cisterns); Obstructive hydrocephalus or posterior fossa mass effect; Coagulopathy or bleeding risk precluding lumbar puncture or CSF access; Inability to safely obtain CSF access.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.